X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Sandoz Initiates New Worldwide Health Inequality Movement

Content Team by Content Team
1st June 2022
in Manufacturing, Middle East and South Asia, News
Sandoz Initiates New Worldwide Health Inequality Movement

Sandoz, a biosimilars manufacturer, has announced the beginning of a new global campaign to combat global health disparities. By harnessing the ‘4 As’ of biosimilars– approval, accessibility, acceptability, and affordability, Act4Biosimilars strives to expand patient access to innovative treatments. A heterogeneous steering committee comprising patient engagement leaders, health professionals, biosimilar experts, and industry executives from around the world has endorsed the effort.

By enabling biological therapies to become more broadly available to people in need of these sophisticated, life-changing treatments, biosimilars have opened a whole new horizon of potential for patients, said Zorana Maravic, CEO of Digestive Cancers Europe. However, unless they address existing biosimilar access disparities, far too many patients will continue to be denied access to the finest treatments available.

Healthcare systems are under more strain than ever before, said Richard Saynor, Sandoz’s chief executive officer. This can be attributed to the expenditures associated with a growing, ageing population as well as more individuals getting struck with chronic diseases. They are happy to be a founding sponsor of Act4Biosimilars, which will spur action to offer these more affordable treatment choices to patients who need them.

The Steering Committee is now working on an action plan that will include the strategies, resources, and activities needed to achieve the global goals. Country indicator maps will be used to track the transformation that is being pushed by groups, associations, and organisations around the world. A biosimilar is a biological drug developed after the patent on the original therapy has expired. In terms of quality, safety, and efficacy, biosimilars also match all of the needed treatment references.

Sandoz was the first company to create and market a biosimilar drug, which was introduced to patients 16 years ago. Ensure equal pricing, involve patients in medical decisions, and streamline biosimilar production are some of the project’s other key goals. By 2030, the eventual goal is to boost worldwide biosimilar medication usage by at least 30% in at least 30 countries.

Previous Post

FDA Grants Novartis Cell Therapy For Follicular Lymphoma

Next Post

Jubilant Gets $146.6M To Expand Its Injectables Production

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Abzena Invests $60M Into cGMP Manufacturing Capacity

Jubilant Gets $146.6M To Expand Its Injectables Production

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In